STALICLA

STALICLA is a clinical-stage biopharmaceutical company, established in Geneva, Switzerland, in 2017, that is advancing precision medicine for neurodevelopmental and neuropsychiatric disorders. The company was founded by Lynn Durham, whose lifelong involvement with the Autism Spectrum Disorder (ASD) community inspired her to address the complexities of diagnosing and treating these conditions. Her background includes experience in business development and healthcare from roles at the World Economic Forum and the Faculty of Medicine of the University of Geneva.

The company's core technology is a proprietary, AI-driven platform called DEPI (Databased Endophenotyping Patient Identification). DEPI integrates and analyzes large datasets, including multi-omics data like metabolomics and genomics, alongside clinical information to identify distinct biological signatures within patient populations. This allows STALICLA to stratify patients into well-defined subgroups, or 'phenotypes', and then match these subgroups with tailored treatment candidates. This methodology moves beyond traditional behavior-based classifications, aiming to improve the success rate of clinical trials and develop personalized therapies. The business model focuses on identifying these patient subgroups and advancing tailored treatments through clinical development, potentially out-licensing assets or forming strategic partnerships.

STALICLA's pipeline includes several therapeutic candidates. STP1 is a combination therapy of two repurposed molecules, ibudilast and bumetanide, tailored for a subgroup designated as 'ASD-Phenotype 1'. Phase 1b trials for STP1 have shown it to be well-tolerated and demonstrated positive signals in improving markers of neurological function. The company is preparing for Phase 2 trials for STP1. Another candidate, STP2 (also known as SFX-01), is being developed for 'ASD-Phenotype 2'. Additionally, STALICLA acquired global rights to mavoglurant from Novartis, now designated STP7. This candidate is being advanced for a subgroup of ASD patients (Phen7) and is also being prepared for a Phase 3 trial for Cocaine Use Disorder (CUD), a study supported by the U.S. National Institute on Drug Abuse (NIDA).

Since its inception, STALICLA has secured significant funding to advance its research and clinical trials, raising over $24.1 million across multiple rounds. A notable Series B financing round in January 2024 brought in $17.4 million, led by SPRIM Global Investments, to fund the preparation for Phase 2 and 3 trials and expand patient identification studies. The company operates with a cross-functional team of drug developers, data scientists, and clinicians in Geneva and Barcelona. STALICLA actively collaborates with a network of leading academic research centers and hospitals in the US and Europe to support its platform and pipeline development. Keywords: precision psychiatry, neurodevelopmental disorders, Autism Spectrum Disorder, clinical-stage biotechnology, DEPI platform, artificial intelligence, drug development, patient stratification, omics-based research, STP1, mavoglurant, substance use disorder, personalized medicine, biopharmaceutical, ASD treatment, clinical trials, genomics, metabolomics, neuroscience, systems biology